3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Conditions
Small Cell Lung Carcinoma
1
Sarcoma
1
Myeloproliferative Disorders
1
Myelodysplastic Syndromes
1
Multiple Myeloma
1
Lymphoma, T-Cell, Peripheral
1
Lymphoma, T-Cell, Cutaneous
1
Lymphoma, T-Cell
1
Lymphoma
1
Liposarcoma
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Leiomyosarcoma
1
Hodgkin Disease
1
Hematologic Neoplasms
1
Hemangiosarcoma
1
Dermatofibrosarcoma
1
Interventions
Doxorubicin
6
pazopanib
5
Gemcitabine
4
pembrolizumab
3
Trabectedin
3
Sorafenib
3
Docetaxel
3
Dacarbazine
3
eribulin
2
Sunitinib
2
Radiotherapy, Conformal
2
Radiotherapy
2
Nivolumab
2
Letrozole
2
Ifosfamide
2
Bevacizumab
2
tremelimumab
1
temsirolimus
1
saracatinib
1
sapanisertib
1
rucaparib
1
romidepsin
1
olaratumab
1
mocetinostat
1
liposomal doxorubicin
1
lenvatinib
1
indolepropanol phosphate
1
durvalumab
1
cixutumumab
1
cabozantinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has results
×
Leiomyosarcoma
×
TTI-621
×
Clear all
NCT04996004
2024-12-11
TTI-621-03
Pfizer
Phase 2
Terminated
76 enrolled
53 charts